Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305924 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
A Phase 2 study of HER2-Negative Breast Cancer and ER Positive Breast Cancer, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05305924 is a Phase 2 study of HER2-Negative Breast Cancer and ER Positive Breast Cancer that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 28 participants, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05305924, a Phase 2 study of HER2-Negative Breast Cancer and ER Positive Breast Cancer, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
Conditions Studied
Interventions
- DRUG Fulvestrant Run-In
Study Locations (1)
Texas
- Houston Methodist Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05305924
The ClinicalTrials.gov registry entry for NCT05305924 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fulvestrant Run-In is the first listed.
NCT05305924 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05305924 about?
NCT05305924 is a clinical study titled "Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer". The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
What is the current status of trial NCT05305924?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2021-02-25. Estimated completion is 2027-12-01.
What conditions does trial NCT05305924 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer, ER Positive Breast Cancer.
What interventions are being tested in trial NCT05305924?
The interventions under investigation include: Fulvestrant Run-In (DRUG).
Who is sponsoring clinical trial NCT05305924?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05305924 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.